Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Key take away from interview - GVHD handover clarification

<< Previous

Bullboard Posts

Next >>

Comment by Jayjayton Aug 15, 2020 8:08am

147 Views

Post# 31412104

RE:RE:Key take away from interview - GVHD handover clarification

why not selling it. And we , shareholders can cet back our investment. The shitt Robert je saying is we gave it back. Wow. If de have no money sell it. Who decided that we Will give back the program??

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market